Golimumab
Top View
- Adalimumab, Etanercept, Infliximab, Certolizumab Pegol, Golimumab
- WO 2018/067987 Al 12 April 2018 (12.04.2018) W !P O PCT
- Antibody Drug Nomenclature: -Umab -Zumab -Ximab
- CIMZIA (Certolizumab Pegol) for Injection, for Subcutaneous Use CIMZIA (Certolizumab Pegol) Injection, for Subcutaneous Use ------CONTRAINDICATIONS------ Initial U.S
- BIOLOGICS & What You Need to Know
- International Nonproprietary Names (INN) for Biological and Biotechnological Substances
- Stelara® (Ustekinumab) – Commercial Medical Benefit Drug
- Medication Guide
- Wo 2010/095940 A2
- Monoclonal Antibodies in Asthma Therapy
- Nivolumab/Ipilimumab Combination Therapy for Melanoma: a Nursing Tool from the Melanoma Nursing Initiative (MNI)
- Biologic Immunomodulators June, 2013 by Larry Dent, Pharm.D., BCPS
- Certolizumab Pegol in Rheumatoid Arthritis: a Review of Phase III Clinical Trials and Its Role in Real-Life Clinical Practice
- Actemra® (Tocilizumab) Injection for Intravenous Infusion
- Adalimumab, Etanercept, Infliximab, Certolizumab Pegol, Golimumab, Tocilizumab and Abatacept for Rheumatoid Arthritis Not Previously Treated with Dmards Or Aft
- Golimumab (Simponi Aria) Ini�Al Dose: 2 Mg/Kg IV at 0 and 4 Weeks
- SIMPONI® (Golimumab) These Highlights Do Not Include All the Information Needed to Use SIMPONI Safely and Effectively
- Drug-Target-Complex Specific Antibodies for Pharmacokinetic Analysis of Biotherapeutics